ArticleBMJ case reports2012
Icatibant and ACE inhibitor angioedema.
Article in BMJ case reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Efficacy of Treatment of Non-hereditary Angioedema.Clinical reviews in allergy & immunology · 2018Pooled it
- A consensus parameter for the evaluation and management of angioedema in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2014Guideline
- Disposition of emergency department patients presenting with angiotensin-converting enzyme inhibitor-induced angioedema.International journal of emergency medicine · 2025Article
- Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review.Case reports in critical care · 2018Article
- Treatment of ACEI-related angioedema with icatibant: a case series.Internal and emergency medicine · 2015Article
- Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts.Internal and emergency medicine · 2014Article
- Delayed presentation of ACE inhibitor-induced angio-oedema.BMJ case reports · 2013Article
- Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema.Allergy and asthma proceedingsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Icatibant is a selective bradykinin 2 receptor antagonist, currently licensed for use in hereditary angioedema. Its benefit in ACE inhibitor angioedema is yet to be fully established. A handful of preliminary case reports suggest that it may be of benefit in reducing both symptom severity and possible hospital or intensive care admission. To date, there are no case reports of the usage of Icatibant in the emergency department in the UK. Here we report our experience of Icatibant in a 62-year-old gentleman presenting with severe oral, pharyngeal and laryngeal oedema while on an ACE inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.